A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...

At 68 weeks, 89.7% of adults with obesity and type 2 diabetes lost 5% or more body weight with CagriSema. Detailed results from the REDEFINE 1 and REDEFINE 2 trials will be presented later in 2025.

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...

Selling CagriSema, if approved ... Hsieh added that the result may prove Zepbound’s mechanism of action — stimulating the gut hormones GLP-1 and GIP — yields better results.

Share price reaction reflects the removal of an upside risk, with some investors hoping that CagriSema would outperform in this pop due to the amylin mechanism, the firm adds. Morgan Stanley ...